Jon Napitupulu

Eledon Pharmaceuticals’ recent Q2 2025 update highlights the emerging potential of its anti-CD40L antibody, tegoprubart, in the complex landscape...

Fortress Biotech’s recent Q2 2025 financial results reveal a company at a pivotal juncture, transitioning from a predominantly development-focused...

IO Biotech’s Phase 3 trial for Cylembio, a potential first-in-class off-the-shelf therapeutic cancer vaccine, in combination with Keytruda (pembrolizumab),...

Bolt Biotherapeutics’ recent financial report reveals a company navigating the challenging biotech landscape, prioritizing its next-generation claudin 18.2 ISAC,...

Pyxis Oncology, a clinical-stage ADC developer, reported second-quarter financials and pipeline updates, highlighting progress in its lead program, micvotabart...

Annexon Biosciences is accelerating its push into the complement-mediated disease market, reporting positive clinical progress across its pipeline and...

Camp4 Therapeutics, a clinical-stage biotech focused on RNA-targeting therapies, recently reported second-quarter financials and provided a key program update....

Macrogenics Charts a Course Toward Focused Growth and Financial Stability Macrogenics, a clinical-stage biopharmaceutical company specializing in antibody-based cancer...

Outlook Therapeutics Achieves First European Sales of Lytenava™ for Wet AMD, Awaits US FDA Decision Outlook Therapeutics has commenced...

Chemomab Therapeutics, a clinical-stage biotech focused on fibro-inflammatory diseases, announced its second-quarter 2025 financial results, highlighting progress in its...